Korean J Intern Med.
2019 Sep;34(5):954-965. 10.3904/kjim.2018.325.
Cellular immunotherapy in multiple myeloma
- Affiliations
-
- 1Research Center for Cancer Immunotherapy, Chonnam National University Hwasun Hospital, Hwasun, Korea. drjejung@chonnam.ac.kr
- 2Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Hwasun, Korea.
- 3Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
- 4VaxCell-Bio Therapeutics, Hwasun, College of Industrial Science, Kongju National University, Yesan, Korea.
- 5Department of Companion and Laboratory Animal Science, College of Industrial Science, Kongju National University, Yesan, Korea.
- KMID: 2457017
- DOI: http://doi.org/10.3904/kjim.2018.325
Abstract
- In multiple myeloma (MM), the impaired function of several types of immune cells favors the tumor's escape from immune surveillance and, therefore, its growth and survival. Tremendous improvements have been made in the treatment of MM over the past decade but cellular immunotherapy using dendritic cells, natural killer cells, and genetically engineered T-cells represent a new therapeutic era. The application of these treatments is growing rapidly, based on their capacity to eradicate MM. In this review, we summarize recent progress in cellular immunotherapy for MM and its future prospects.
